EXCITATORY amino acids have been implicated as important mediators in the process of neuronal cell death in hypoxia, ischaemia and chronic neurodegenerative diseases (Choi et al., 1995; Coyle & Puttfarken, 1993; Dodd et al., 1994; Maragos et al., 1987; Rothman & Olney, 1986) . During cerebral ischaemia excessive release of the excitatory neurotransmitter glutamate is observed (Benveniste et al., 1984) , which leads to an uncontrolled rise of intracellular free Ca 2ϩ (Dubinsky, 1993) and ultimately to neuronal necrosis (Randall & Thayer, 1992) . Massive entry through various channels of Ca 2ϩ into neurons is considered to be the final common pathway leading to irreversible neuronal damage, since persistent high levels of cytosolic free Ca 2ϩ may evoke dysregulations of Ca 2ϩ activated processes which are detrimental to neurons (Clapham, 1995) . Both N-methyl-D-aspartate (NMDA) receptoroperated ion channels and voltage-dependent Ca 2ϩ channels (VDCCs) appear to be largely responsible for the massive Ca 2ϩ influx during excitotoxic insults (Garcia et al., 1994; Hartley et al., 1993; Lobner & Lipton, 1993; Rothman & Olney, 1995) . During the initial phase of ischaemia Ca 2ϩ influx is shown to be mediated primarily by stimulated NMDA-channels followed by a secondary influx involving other Ca 2ϩ channels (Lobner & Lipton, 1993 ) activated by voltage changes or intracellular messenger systems (Chetkovich et al., 1991; Garcia et al., 1994; Skeen et al., 1994) . Agents that block the Ca 2+ entry through activated NMDA-channels have been demonstrated in several ischaemia model studies to decrease neuronal damage Meldrum & Garthwaite, 1990; Siesjö et al., 1992) . Other reports indicate that also blockade of the VDCCs and notably the L-type channels by dihydropyridines provide a remarkable neuroprotection in experimental ischaemia (Bellemann et al., 1983; Langley & Sorkin, 1989; Nuglisch et al., 1990; Rami & Krieglstein 1994; Scriabine et al., 1989) .
In the present study we evaluated combined treatment with a noncompetitive NMDA-receptor antagonist (MK-801) and a voltage dependent L-type Ca 2ϩ channel blocker (nimodipine) for its neuroprotective effects against NMDA-induced neuronal injury. Both MK-801 (dizocilipine) and nimodipine (a 1,4-dihydropyridine derivate, BAY E 9736) have been demonstrated to attenuate brain injury following experimental ischaemia and excitotoxic insults Luiten et al., 1995; McDonald et al., 1990; Nakamura et al., 1993; Nuglisch et al., 1990) .
In the currently used model NMDA was unilaterally injected in the cholinergic cell groups of the magnocellular nucleus basalis (MBN), which have axonal projections to the ipsilateral cortex (Fig. 1) . Neuronal injury was measured on the reductions of cholinergic axonal fibres in the injected hemisphere, whereby the cholinergic innervation of the intact contralateral side served as internal control. In our previous study this in vivo model was proven to be very suitable and reliable for quantitative assessment of neuroprotective properties of potentially beneficial agents (Luiten et al., 1995) .
First we examined dose dependent neuroprotective effects of pretreatment with MK-801 to select an appropriate dose for testing a combined therapy with nimodipine. Secondly the neuroprotective impact of the combination therapy was compared to the effects of single drug treatments with MK-801 and nimodipine. Finally we investigated the temporal course of neuroprotection, by measuring the degree of neuroprotection of both drugs applied at several time points before and after NMDA-exposure.
Materials and Methods

Subjects and treatments
The experiments of the present study were carried out on a total of 51 young adult (3 month old) male Wistar rats (average body weight 320 g) bred in our own facilities. The animals were housed at a standard temperature of 23 Ϯ 1°C in a light controlled room (lights on from 07.00 h to 19.00 h). All rats had free access to either standard food pellets (Sniff, Soest, FRG) or (in case of nimodipine treatment) to identical pellets containing nimodipine at a concentration of 860 ppm.
Animals were divided and allocated to two experiments. In the first experiment the neuroprotective effects of three different doses MK-801, applied 2 h before NMDA-infusion, were determined to select an appropriate dose for testing a combined treatment with nimodipine. In the second experiment the neuroprotective effects of a combined therapy with MK-801 and nimodipine were compared with the effects of single treatments with either of these drugs against NMDA-neurotoxicity. To study the temporal profile of potential neuroprotection, in the latter experiment combined and single drug therapy was also applied 8 min and 2 h after NMDA-injection. These time points were chosen based on previous reports, studying the temporal course of excitoxicity processes due to NMDA exposure, showing an initial calcium influx within 30 min after NMDA-application (Van Lookeren Campagne et al., 1994; Tymianski et al., 1993) . The 8 min interval was chosen for practical reasons. At this moment the animals could be removed from the stereotaxic frame, so that a proper i.p. injection could be performed.
Experiment I
To study the effects of three different doses MK-801 on NMDA-induced neuronal injury, 22 animals were divided into four groups: (1) controls with NMDA-injections in the MBN, but receiving no drug treatment at all (n ϭ 6); (2) rats receiving 1 mg/kg MK-801 (n ϭ 5); (3) rats receiving 3 mg/kg MK-801 (n ϭ 6); and (4) a group of animals receiving 5 mg/kg MK-801 (n ϭ 6). MK-801 was dissolved in phosphate buffered saline, pH 7.4 (PBS) and i.p. injected 2 h before NMDA-infusion. The controls of the first experiment also served as controls for the second experiment. 
Experiment II
From the results of the first experiment the dose of 5 mg/kg MK-801 was selected for further study of the neuroprotection by a combined therapy of MK-801 and nimodipine. For investigating the temporal course of protection, besides pretreatment, drugs were applied 8 min and 2 h after NMDAexposure in different groups. For pretreatment with nimodipine, rats received food pellets containing 860 ppm nimodipine starting 2 weeks prior to NMDA-injection. The concentration 860 ppm was chosen because it was shown in a number of studies to be an optimal dose yielding neuroprotective effects (Schuurman et al., 1987; Scriabine et al., 1989; De Jong et al., 1992) , without affecting brain metabolism (Harper et al., 1981) , blood pressure or circulation parameters (Kazda et al.,1985) . During the period of nimodipine application in food, the daily food intake was measured. Posttreatment with nimodipine consisted of an 15 mg/kg i.p. injection with nimodipine dissolved in a mixture of ethanol and polyethylene glycol (2:1). The various groups in experiment II are summarized in Table 1 .
Surgical procedure
Excitotoxic damage to the MBN in all cases was carried out unilaterally in the right hemisphere, such that the intact left hemisphere served as a control for each individual case. The animals were anaesthetized with a combination of sodium pentobarbital (30 mg/kg i.p.) and hypnorm (Duphar, Weesp, Netherlands, 0.4 mg/kg i.m.). The anticholinergicum atropine-sulphate (0.5 mg/kg i.p.) was used to limit salivary bronchial secretion. Rats were positioned in a stereotaxic frame, the head skin was retracted and a small hole was drilled in the skull. For the toxin injections a 5 µl Hamilton syringe was positioned in the MBN at the coordinates 1.5 mm posterior to bregma and 3.2 mm lateral to the midline (defined by the atlas of Paxinos & Watson, 1986) . At two dorso-ventral positions, 6.2 mm and 7.0 mm ventral to the dura, 0.5 µl PBS containing 30 nmol of a racemic mixture of N-methyl-D,L-aspartate (Sigma, St. Louis) was slowly injected in steps of 0.1 µl, so that a total of 60 nmol was injected in the MBN. After each injection the needle was left in situ for 5 min to allow for diffusion and to limit spread of the toxin solution during withdrawal of the needle. The dose of 60 nmol was shown in a previous study (Luiten et al., 1995) to result in a 66% reduction of cholinergic fibres projecting to the ipsilateral cortex. Therefore this dose was considered as suitable for studying neuroprotective potentials of the used compounds. After surgery, all animals survived for 12 days until sacrifice and histological processing.
Tissue processing and histochemistry
Fixation of the brain was carried out by transcardial perfusion with 300 ml fixative composed of 2.5% paraformaldehyde, 0.05% glutardialdehyde and 0.2% picric acid in 0.1 M phosphate buffer (PB, pH 7.4) at a perfusion speed of 20 ml/min, which was preceded by a short prerinse of heparinized saline. The brains were removed from the skull and cryoprotected by overnight storage at 4°C in 30% sucrose in 0.1 M PB. Subsequently, the brains were coronally sectioned on a cryostat microtome at a thickness of 20 µm. Before sectioning, the left hemisphere (control side) was marked by punching a small needle hole in the corpus callosum. The free floating brain sections were postfixed by immersion in a 2.5% glutardialdehyde solution in PBS overnight at 4°C. Hereafter, the cholinergic fibres were visualized by staining for the presence of acetylcholinesterase (AChE) according to Hedreen et al. (1985) using a silvernitrate intensification procedure. Finally, the sections were mounted, dehydrated, cover-slipped and examined by light microscopy.
To determine the effect of the neuronal injury in the MBN, the cholinergic fibre density was measured in layer V of the posterior somatosensory cortex in both the left (control side) and right (injection side) hemispheres. Fibre densities were assessed by means of counting fibre crossings with the lines of an in-built ocular counting grid, described in detail by Luiten et al. (1995) . Crossing fibres were counted in three sections, representing a cortical region receiving the densest cholinergic innervation from the damaged MBN division (Luiten et al., 1987) . Comparison between the counted fibre crossings at the injected side and counted values at the intact control side revealed the percentage fibre reduction, which was considered to be proportional to the degree of neurotoxic cell damage. This way a relative value was obtained that was insensitive to individual variations between cases that might occur for technical or other reasons. Percentage neuroprotection for each experimental drug treatment was calculated by the ratio of fibre reduction after NMDA-injection with [X] and without drug application [C] , according to the following formula:
Statistical analysis
To examine a dose-dependent influence of MK-801 on fibre reduction after NMDA-induced injury one-way analysis of variance (ANOVA) was performed. ANOVA was carried out also to define the temporal profile of neuroprotection by combined therapy with nimodipine and MK-801. The nonparametric Mann-Whitney-U test (STATS program) was used for comparison between the effects of the different treatments on fibre reduction after neurotoxic injury of the MBN. A P value less than 0.05 was considered to indicate statistical significance. Data are presented as mean Ϯ standard error of the mean (SEM). 
n ϭ 6 n ϭ 6 n ϭ 6 Nimodipine ϩ MK-801 n ϭ 6 n ϭ 8 n ϭ 6
Results
Experiment I
Unilateral injections of NMDA in the MBN complex of non-drug treated animals (controls) resulted in a profound decrease of cholinergic fibres in a large part of the ipsilateral cortex, corresponding with the unilaterally organized anatomical pattern of MBN projections to the cortex in the rat. In the majority of the animals NMDA induced seizures which appeared after surgery when consciousness was regained. The seizures disappeared again within 2 h. A 66.2 Ϯ 3.3% reduction of fibre density was measured 12 days after the NMDA-infusion. All doses of MK-801 applied 2 h before MBN injection significantly attenuated NMDAinduced cortical fibre reduction compared to controls (P Ͻ 0.01, Fig. 2 ). Fibre loss was reduced in a dosedependent way (one-way ANOVA P Ͻ 0.001). The dose of 1 mg/kg MK-801 revealed a neuroprotection of 37.7%, while for 3 mg/kg and 5 mg/kg MK-801 neuroprotection was calculated as 46.0% and 72.3%, respectively.
Experiment II
The dose of 5 mg/kg MK-801 from the first experiment was selected for further investigating a combined treatment of MK-801 and nimodipine. In case of nimodipine application in food pellets (860 ppm), food intake ranged from 20 to 26 g/day, which signified a daily nimodipine intake of 17 to 22 mg. Treatment with a nimodipine diet starting two weeks before NMDAinfusion attenuated the NMDA-induced cortical fibre reduction from 66.2 Ϯ 3.3% (controls) to 47.2 Ϯ 5.6% (P Ͻ 0.01), providing a neuroprotection of 28.8% (Fig.  3 , Table 2 ). Combination of pretreatments of MK-801 together with nimodipine potently antagonized NMDAinduced neuronal injury and subsequent cholinergic fibre decline. Denervation values were strikingly reduced to only 6.7 Ϯ 1.5% (P Ͻ 0.01 vs control) and approached our previously found fibre reductions (4.7%) in sham operated animals infused with vehicle solution (Luiten et al., 1995) . The neuroprotective effects of the combined treatment were significantly higher (P Ͻ 0.01) than the effects of single drug treatments. Application of nimodipine together with MK-801 yielded a protection of 89.4% against the excitotoxic effects of NMDA. Concerning single drug therapy, protective effects of posttreatment 8 min after NMDA-exposure were not significantly different from the effects of pretreatment. However, combined treatment with nimodipine and MK-801 pretreatment was significantly (P Ͻ 0.01) more effective than treatment 8 min after NMDA-injection. With regard to the start of the combined therapy or single drug application of nimodipine (15 mg/kg i.p.) and MK-801 (5 mg/kg i.p.) after NMDA-injection, the degree of protection showed a time-dependent effect (ANOVA, P Ͻ 0.01). Combined nimodipine/MK-801 treatment 8 min after NMDA-injections revealed 81.9% protection. Application 2 h later resulted in significantly more fibre loss but protection values still measured up to 65.5%. Single drug treatments showed significantly lower protective results at both time points (P Ͻ 0.01). It was noteworthy that nimodipine alone applied 2 h after NMDA-exposure revealed no significant protection, whereas combined with MK-801 it resulted in significantly (P Ͻ 0.01) higher protection values compared to single MK-801 application.
Discussion
In the present study we demonstrated that the combined therapy with a non-competitive NMDA-antagonist (MK-801) and an L-type VDCC blocker (nimodipine) exerted an additional protective influence against NMDA-induced toxicity to cholinergic neurons in the nucleus basalis. The additional protective effect of MK-801 and nimodipine has also been reported in models of ischaemia and in tissue trauma in culture (Greenberg et al., 1990; Rod & Auer, 1992; Uematsu et al., 1991; Regan & Choi, 1994) . Furthermore, the degree of protection showed a timedependent effect with regard to the start of the drug treatment after the NMDA-injection. A 73% protection achieved by the highest MK-801 dose (5 mg/kg) applied before NMDA-injection was further increased to 89% by additional nimodipine treatment. In a previous study we already showed that nimodipine treatment prior to NMDA-exposure provided almost 30% neuroprotection indicating the involvement of activated VDCCs in the NMDAinduced neurodegenerative process (Luiten et al., 1995) . The present data suggest that also in case of a strong neuronal protection against NMDAinduced neuronal damage by NMDA-antagonists, simultaneous blockade of VDCC-mediated Ca 2ϩ currents can additionally and significantly inhibit the process of neuronal damage.
In the initial phase of NMDA-overstimulation as in ischaemic conditions Ca 2ϩ influx depends primarily on NMDA-channels (Bading et al., 1995; Garcia et al., 1994) . There are good arguments that secondary Ca 2ϩ currents through activated VDCC are involved in the later stages of NMDA-induced cell damage (Garcia et al., 1994; Lobner & Lipton, 1993) . Several mechanisms may underlie increase of Ca 2ϩ currents through VDCCs after overstimulation by NMDA. Firstly, membrane depolarization caused by NMDA-channel activation can trigger additional Ca 2ϩ influx through neighbouring VDCCs (Skeen et al.,1993) . Intracellular messenger systems, including cAMP associated pathways, are thought to be involved in the delayed longterm enhancement of voltage-gated Ca 2ϩ currents after NMDA-receptor stimulation (Chetkovich et al., 1991; Garcia et al., 1994; Mironov & Lux, 1992) .
Pretreatment with MK-801 and nimodipine yielded a neuroprotection of 89% while application of this drug combination 8 min and 2 h after injection generated a protection of 82% and 66%, respectively. Based on these observations it may be concluded that up to 2 h after NMDA-injection a blockade of NMDA-receptor-and VDCC-mediated Ca 2+ currents is able to protect the majority of neurons against NMDA-induced neurotoxicity. However, these results also indicate that a part of the neurons which benefit from protection by nimodipine and MK-801 when these drugs are given before and shortly after (8 min) the neurotoxic event, cannot be prevented from neuronal death by the drug application 2 h after NMDA-injection. Early neurotoxicity during the first 2 h after NMDA-exposure, exerted by the initial massive Ca 2ϩ influx may explain this early irreversible cell damage. Studies in which single neurons in culture were lethally challenged with excitatory amino acids showed an initial Ca 2ϩ influx through NMDA-channels followed by a delayed secondary, sustained and irreversible Ca 2ϩ rise indicating imminent cell death (Randall & Thayer, 1992; Tymianski et al., 1993) . Early blockade of Ca 2ϩ influx by NMDA-antagonists was able to prevent this early cell death (Hartley et al., 1993; Tymianski et al., 1993 ). An initial massive Ca 2ϩ transient is considered also to be a critical step in triggering delayed neuronal death. Blockade of NMDA-channels may thus provide the highest degree of neuroprotection in the early phase of excitotoxicity. However, it appears in our currently used in vivo excitotoxicity model that still more than 60% protection can be achieved by blockade of NMDA-and voltage-dependent Ca 2ϩ currents at 2 h after NMDA-infusion.
Other in vivo studies have also reported a striking neuroprotection by MK-801 alone when applied several hours after NMDA-exposure Van Lookeren Campagne et al., 1994) . It seems likely that in particular neurons in the centre of the NMDAinjection site, where the NMDA-concentration is highest, will be irreversibly affected by an initial NMDA-mediated massive Ca 2ϩ influx. By diffusion NMDA will reach other neurons in a later stage and a lower concentration. Therefore remaining majority of neurons may be affected by slow and reversible neurotoxic processes involving Ca 2ϩ influxes through activated VDCCs and NMDA-channels. Currently, time dependent regional calcium accumulation is investigated in our NMDA-toxicity model by 45 Caautoradiograpy, to elucidate the time-dependent process of excitotoxic damage in the NBM.
Based on the observations of delayed enhancement of voltage-dependent Ca 2ϩ currents after NMDAoverstimulation (Randall & Thayer, 1992; Tymianski et al., 1993) , we would expect a longer lasting neuroprotective potential of nimodipine. Surprisingly, nimodipine alone applied 2 h after NMDA-exposure revealed no significant neuroprotection, compared to a still strongly protective effect established by MK-801. This finding demonstrates that at this stage of excitotoxic insult blockade of activated NMDA-channels is more effective in inhibition of NMDA-neurotoxicity than antagonizing L-type Ca 2ϩ -channels. These observations suggest that mainly activated NMDA-channels are involved in the later stages of NMDA-induced neurotoxic processes. However, in this period of delayed cell death nimodipine combined with MK-801 was able to reduce neuronal damage to a significantly higher level compared to the protective effects of MK-801 alone. Presumably, during single NMDA-receptor blockade [Ca 2ϩ ] i will still reach lethal levels in some neurons, which can be prevented by an additional VDCC blockade. More detailed analysis of the cytology of cellular damage in the injected region, as currently investigated by us, is necessary to materialize these assumptions.
In conclusion, the present data show that dual blockade of NMDA-channels and VDCCs reveals an additional neuroprotective effect against NMDAneurotoxicity. The degree of neuroprotection by this therapy is slowly decreased concomitant with the delay of application after NMDA-injection. Early treatment with this drug combination will yield optimal neuroprotection by blocking an initially triggered influx of Ca 2ϩ . However, by dual blockade of both classes of Ca 2ϩ -channels after this initial phase of Ca 2ϩ -overload, there is still a significant potential for reversing NMDA-induced neurotoxic processes.
